BIOPHAGE PHARMA (fka BIPMF)

[oasdihf]

Biophage Pharma signs its first client in the nuclear energy industry for Beryllium sensitization testing

11:29 EST Monday, March 13, 2006

Zircatec Precision Industries, a subsidiary of the world's largest uranium producer

MONTREAL, March 13 /CNW Telbec/ - (TSX.V: BUG). Biophage Pharma today announced that it has received a significant order for Beryllium testing of workers at Zircatec Precision Industries. Zircatec is a leading supplier of CANDU fuel, nuclear products and technology to the global nuclear industry. Cameco controls 100% of Zircatec which operates facilities at Port Hope and Cobourg, Ontario. "Biophage is a premier provider of beryllium hypersensitivity testing in Canada and is also actively working on expanding this service to the United States. Each day more companies are becoming aware of the health issues surrounding exposure of beryllium-sensitized workers. This is reflected by the increasing number of tests we are performing each year" said Dr. Rosemonde Mandeville, President and Chief Executive Officer.

Biophage is also pleased to confirm the signature of the exclusive licensing agreement announced by press release on March 1, 2006, as well as an agreement with MELISA Diagnostics Ltd. to issue, as partial consideration for the exclusive license, an aggregate of 200,000 warrants in favor of Professor Vera Stejskal and MELISA Diagnostics Ltd. Each such warrant entitles its holder to purchase one common share of the corporation at an exercise price of $0.11 per share until February 24, 2008. The agreement also provides for the payment of royalties on net sales of the metal allergy blood test. The issuance of warrants is subject to regulatory approval. "The exclusive licensing agreement signed with MELISA Diagnostics Ltd and Prof Vera Stejskal will allow us to extend the panel of tests in occupational medicine by offering to our clients the possibility to identify allergies to more than 20 different metals and a large number of allergens from a single blood sample." concluded Dr Mandeville.

About Biophage Pharma Inc.

Biophage Pharma Inc. is a high potential Canadian company focused on the development of novel phage-based Biosensors for live pathogen diagnostics. Founded in 1995, Biophage has now completed the first prototype development of its proprietary PDS(R) Biosensor and is entering in the pre-commercialization stage. The unique feature of this product is its ability to detect not only the presence, but also the viability of pathogens. Recent advances have demonstrated that the PDS(R) Biosensor can be used to evaluate clinical sensitivity to antibiotics. This Biosensor has a wide range of potential applications in water safety, food and feed quality and safety, homeland security and in the medical field where protecting against even small number of bacteria infiltration is important (i.e., blood banks, stem cells and sperm banks). The company has also an important profit center that actually provides services in Immunology/Immunotoxicology, in Beryllium hypersensitivity testing and now allergy to more than 20 different metals and a large number of allergens. (www.biophagepharma.com)

About MELISA(R) Technology

The MELISA(R) technology is protected by a patent and European, Canadian and US trademarks. The MELISA(R) test was developed by Prof Vera Stejskal, former head of immunotoxicology division at ASTRA Pharmaceuticals (now AstraZeneca), to screen for drug allergy in workers in pharmaceutical factories. Using a blood sample, MELISA(R) can detect and measure hypersensitivity to metals and many other substances. In Europe, it has been used for over 10 years, mainly by chronic disease specialists and dentists. This licensing is MELISA's biggest move into occupational screening markets and marks its Canadian debut (www.melisa.org).

The TSX Venture Exchange has not reviewed and does not accept any

responsibility for the accuracy of this release.

%SEDAR: 00014714EF

For further information: Biophage Pharma Inc: Rosemonde Mandeville, M.B., Ch.B., PhD., President and Chief Executive Officer, Biophage Pharma Inc., [phone], [e-mail]; Carpe DM, Inc.: Stuart Fine, Investor Relations, [phone], [e-mail]; Renmark Financial Communications Inc.: Christine Stewart, [e-mail]; Sylvain Laberge, [e-mail], [phone], Fax : [phone], www.renmarkfinancial.com; MELISA Diagnostics Ltd: Linda Stejskal, Communications director, London, United Kingdom, ([phone], [e-mail]